A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg; CLARITY Study Group

doi:10.1056/NEJMoa0902533

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Gavin Giovannoni
, Giancarlo Comi
, Stuart Cook
, Kottil Rammohan
, Peter Rieckmann
, Per Soelberg Sørensen
, Patrick Vermersch
, Peter Chang
, Anthony Hamlett
, Bruno Musch
, Steven J Greenberg
, CLARITY Study Group

Department of Neurology

918 Citations (Scopus)

Abstract

Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

Original language	English
Journal	New England Journal of Medicine
Volume	362
Issue number	5
Pages (from-to)	416-26
Number of pages	11
ISSN	0028-4793
DOIs	https://doi.org/10.1056/NEJMoa0902533
Publication status	Published - 4 Feb 2010

Access to Document

10.1056/NEJMoa0902533

Cite this

@article{8d0197921cee4b6880963fcc8f4fddb2,

title = "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis",

abstract = "Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.",

author = "Gavin Giovannoni and Giancarlo Comi and Stuart Cook and Kottil Rammohan and Peter Rieckmann and \{Soelberg S{\o}rensen\}, Per and Patrick Vermersch and Peter Chang and Anthony Hamlett and Bruno Musch and Greenberg, \{Steven J\} and \{CLARITY Study Group\}",

note = "2010 Massachusetts Medical Society",

year = "2010",

month = feb,

day = "4",

doi = "10.1056/NEJMoa0902533",

language = "English",

volume = "362",

pages = "416--26",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "5",

}

TY - JOUR

T1 - A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

AU - Giovannoni, Gavin

AU - Comi, Giancarlo

AU - Cook, Stuart

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Soelberg Sørensen, Per

AU - Vermersch, Patrick

AU - Chang, Peter

AU - Hamlett, Anthony

AU - Musch, Bruno

AU - Greenberg, Steven J

AU - CLARITY Study Group

N1 - 2010 Massachusetts Medical Society

PY - 2010/2/4

Y1 - 2010/2/4

N2 - Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

AB - Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.

U2 - 10.1056/NEJMoa0902533

DO - 10.1056/NEJMoa0902533

M3 - Journal article

C2 - 20089960

SN - 0028-4793

VL - 362

SP - 416

EP - 426

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 5

ER -

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Abstract

Access to Document

Fingerprint

Cite this